Overview

Update
Total Equity Funding
$6.5M in 1 Round from 3 Investors
Most Recent Funding
$6.5M Series B on July 6, 2011
Headquarters:
Chilworth
Description:
Vantia Therapeutics is a pharmaceutical company developing small molecule drugs for unmet medical needs.
Founders:
Categories:
Biotechnology
Website:
http://www.vantia.com
Social:

Company Details

Update

Vantia Therapeutics is an emerging pharmaceutical company developing novel, small molecule drugs targeting large areas of unmet medical need. Its strong clinical pipeline includes VA106483 for nocturia and VA111913 for dysmenorrhoea, which directly target indications that together affect many millions of people, are poorly treated and represent billion dollar markets. Vantia's strategy is to develop its proprietary drug candidates through Phase II clinical testing and then commercialise through partnerships. The Company was founded in 2008 and is backed by specialist life science investors Novo A/S, SV Life Sciences and MVM Life Science Partners.

Funding Rounds (1) - $6.5M

Update
DateAmount / RoundValuationLead InvestorInvestors
Jul, 2011$6.5M / Series B3

Board Members and Advisors (2)

Update

Offices/Locations (1)

Update
  • Office

    Southampton Science Park

    1 Venture Road, Southampton,

    Chilworth, SO16 7NP

    GBR

Past Team (2)

Update

Add Acquisitions

Add Current Team

Add Products

Add Sub Organizations

Add Competitors

Add Memberships

Add Customers

Add Partners

Add Images

Add Videos